NuCana Presents Data On NUC-7738 At AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics 2023
Portfolio Pulse from Benzinga Newsdesk
NuCana presented data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023. The drug has been well tolerated both as a monotherapy and in combination with pembrolizumab, showing signs of efficacy including tumor volume reductions and prolonged time on treatment.
October 16, 2023 | 11:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NuCana's NUC-7738 has shown promising results in both monotherapy and combination cohorts, which could potentially boost the company's stock.
The positive data presented by NuCana on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 could potentially boost investor confidence in the company, leading to a rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100